Piroxicam-β-Cyclodextrin

@article{Lee2012PiroxicamCyclodextrin,
  title={Piroxicam-$\beta$-Cyclodextrin},
  author={C. Rhoda Lee and Julia Balfour},
  journal={Drugs},
  year={2012},
  volume={48},
  pages={907-929}
}
SynopsisPiroxicam-β-cyclodextrin is a complex of the established nonsteroidal antiinflammatory drug (NSAID) piroxicam and an inert cyclic macromolecule, β-cyclodextrin. In clinical trials in patients with rheumatic diseases or pain arising from other conditions, it was as effective an analgesic as standard piroxicam, and showed a faster onset of action on the first day of treatment.In short term pharmacodynamic studies in healthy volunteers, piroxicam-β-cyclodextrin was equivalent to or tended… 
Methylene-Tethered Arylsulfonation and Benzotriazolation of Aryl/Heteroaryl C-H Bonds with DMSO as a One-Carbon Surrogate.
TLDR
The mechanistic insights show that the intermediate 3-((methylthio)methyl)-2-phenylimidazo[1,2-a]pyridine is generated from imidazopyridine, DMSO, and Selectfluor.
Exploring the novel green eutectic solvent for the synthesis of 4-hydroxy-2-methyl-N-2-pyridinyl-2H-1,2,-benzothiazine-3-carboxamide 1,1-dioxide with benzoic acid cocrystal using a co-grinding technique
In the present study, the suitability of a green eutectic solvent, a mixture of menthol and camphor for cocrystal synthesis has been investigated to improve the biopharmaceutical properties of poorly
Piroxicam.
Synthesis of Densely Substituted Sulfonylfurans and Dihydrofurans via Cascade Reactions of α-Functionalized Nitroalkenes with β-Ketosulfones.
TLDR
Reaction of β-ketosulfones with different α-functionalized nitroalkenes affords diversely substituted sulfonyl furans and dihydrofurans in excellent yields with broad substrate scope, demonstrating the synthetic efficiency of the methodology.
A Novel Approach for the Control of Inflammatory Pain: Prostaglandin E2 Complexation by Randomly Methylated &bgr;-Cyclodextrins
TLDR
Capture of PGs by cyclodextrins could be a novel and innovative tool for the treatment of inflammatory pain and bypassing some unwanted side effects of cyclooxygenase inhibitors.
An Unexpected Domino Reaction of β‐Keto Sulfones with Acetylene Ketones Promoted by Base: Facile Synthesis of 3(2H)‐Furanones and Sulfonylbenzenes
An unexpected domino reaction of β-keto sulfones with acetylene ketones has been developed. The domino reaction of β-keto sulfones with diynones proceeded smoothly in the 30% mol K2CO3 without other
Piroxicam/β-cyclodextrin complex included in cellulose derivatives-based matrix microspheres as new solid dispersion-controlled release formulations
New formulations capable to enhance piroxicam (PRX) water solubility and at the same time to control and adjust its release have been developed. For this purpose, two methods have been used and
Enhanced analgesic activity by cyclodextrins – a systematic review and meta-analysis
TLDR
A systematic review to evaluate the analgesic activity of compounds complexed in cyclodextrins, analyzing whether these complexes improved analgesic efficacy found that the complexed drug had a significantly (p < 0.01) greater effect than the non-complexed drug.
...
1
2
3
...

References

SHOWING 1-10 OF 61 REFERENCES
Dissociation Between the Antinociceptive and Anti-Inflammatory Effects of the Nonsteroidal Anti-Inflammatory Drugs
SummaryThe authors challenge the general view that the analgesic effect of the nonsteroidal anti-inflammatory drugs (NSAIDs) can be universally attributed to their inhibitory effects on the synthesis
Placebo-controlled comparison of piroxicam-β-cyclodextrin, piroxicam, and indomethacin on gastric potential difference and mucosal injury in humans
TLDR
The results indicate that piroxicam-β-cyclodextrin exerts less direct acute damage on the gastric mucosa, and appears to be less gastrolesive than either indomethacin or the standard piroXicam formulation when administered short-term.
Comparison of faecal blood loss, upper gastrointestinal mucosal integrity and symptoms after piroxicam beta-cyclodextrin, piroxicam and placebo administration
TLDR
Daily mean gastrointestinal blood loss was greater in the piroxicam group than in either the CHF 1194 or placebo groups, but the difference was not significant, due to the small number of piroXicam-treated subjects who completed the study.
Oral bioavailability of CHF1194, an inclusion complex of piroxicam and β-cyclodextrin, in healthy subjects under single dose and steady-state conditions
TLDR
The pharmacokinetics of piroxicam was linear after the doses used here, suggesting that long term treatment with CHF1194 should not require any change in dosing regimen.
Epidemiology of Gastrointestinal Damage Associated with Nonsteroidal Anti-Inflammatory Drugs
TLDR
Nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with significant upper gastrointestinal (GI) toxicity, with a relative risk of approximately 3.5%, andTherapeutic alternatives which may confer a lower risk of significant GI toxicity include enteric-coated preparations, non-acetylated salicylates, and NSAIDs taken in conjunction with misoprostol.
Non-steroidal anti-inflammatory drugs: how do they damage the gut?
TLDR
This review will highlight the epidemiology of NSAID-induced gastrointestinal toxicity, their effects on prostaglandins, and the phenomenon of cytoprotection, as well as the effects of NSAIDs on the small intestine and colon.
Pharmacokinetics of Oxicam Nonsteroidal Anti-Inflammatory Agents
TLDR
Although the development of sudoxicam was stopped because of frequent adverse effects, this drug is interesting because, unlike other oxicams, its appears to have nonlinear elimination pharmacokinetics.
...
1
2
3
4
5
...